Founded in 1998, the biotechnology company Seattle Genetics, Inc is focused on developing and commercializing effective autoimmune diseases and cancer treatment therapies. As a result of their unwavering commitment to superior research and clinical development, they have developed the antibody-drug conjugate ADCETRIS, or brentuximab vedotin that has been a major breakthrough in the treatment of cancer.
It has led to a significant improvement in clinical outcomes. The entire 800+ member staff at Seattle Genetics, which has its headquarters in Bothell, Washington,
dedicates their time and talent to finding remedies and cures to meet the needs of cancer patients.
Seattle Genetics has partnered with several companies Genentech and Takeda Pharmaceuticals to advance the marketing and product pipeline for its antibody based therapies. They are conducting clinical trials on several excellent product candidates for treating cancer and one autoimmune disease treatment. The company also has a number of innovative preclinical treatments under development that show great promise. The proprietary treatment ADCETRIS is approved for use in over 60 countries.
A driving force behind Seattle Genetics is co-founder Clay B. Siegall. The company’s president, CEO and board chairman, Dr. Siegall is a scientist that has been working on targeted cancer therapies for many years. He built the company on rigorous research, scientific innovation and a passion for seeking solutions for cancer patients. Dr. Siegall is part of the Seattle Genetics leadership that has focused on the creation of effective drug development practices. He has been instrumental in helping the company to its leadership position in the development of antibody-drug conjugates.
Dr. Siegall worked to get Seattle Genetics’ ADC technology multiple strategic licenses. Those licenses have garnered the in excess of $325 million through the partnerships with AbbVie, GlaxoSmithKline, Genentech and Pfizer. He has also led their capital raising activities using public and private financing which has totaled over $1.2 billion. Before starting Seattle Genetics, Dr. Siegall worked with the National Institutes of Health, the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute. He has also earned numerous prestigious awards, published extensively, holds 15 patents and serves the board of several pharmaceutical companies.
Learn more here: